GPX4 and non-small cell lung carcinoma: Intriguingly, it has been found in EGFR+ NSCLC cells that a sequential treatment with EGFR‐TKIs plus trametinib or dasatinib following these TKIs plus GPX4 inhibitor has potent efficacy to inhibit cell growth as compared to treatment with these TKIs [42].